RBC Capital raised the firm’s price target on 4D Molecular to $35 from $25 and keeps an Outperform rating on the shares. The company’s Phase 2 wet AMD gene therapy data readout checks all the boxes and exceeds expectations outlined by the firm’s key opinion leaders, with below 5% inflammation and above 75% “reduction in injection burden”, the analyst tells investors in a research note, adding that proceeding with a pivotal trial is “the right move”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FDMT:
- 4D Molecular presents interim data from Randomized Phase 2 PRISM trial
- 4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
- 4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
- 4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
- 4D Molecular receives RPDD from FDA for aerosolized 4D-710
